Cytokine Profile in Children with Severe Multisystem Inflammatory Syndrome Related to the Coronavirus Disease 2019

Abstract

The multisystem inflammatory syndrome in children (MIS-C) is a novel and concerning entity related to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Although MIS-C has been the subject of intensive research efforts, its pathophysiology and optimal treatment remain elusive. We studied the clinical features, laboratory findings, and immunoinflammatory profiles of seven children prospectively admitted to a pediatric intensive care unit (PICU) during the first wave of the pandemic. All patients had immunoglobulin (Ig)-G against SARS-CoV-2, four of seven patients had both IgM and IgG, and in one of the 7 SARS-CoV-2 was detected in a respiratory sample. All patients received intravenous fluid boluses (median: 15 mL/kg) and norepinephrine. The most common form of respiratory support was supplemental oxygen via nasal cannula. None of the patients needed mechanical ventilation. The cardiovascular system was frequently involved. All patients had an elevated troponin-I (median: 107.3 ng/L). Four out of seven patients had coronary artery abnormalities, and two of seven had both abnormal electrocardiogram (EKG) findings and evidence of left ventricular dysfunction on echocardiogram. Ig levels and complement function were normal. Peripheral blood phenotyping with flow cytometry showed decreased T-cell numbers at the expense of CD8+ T-cells. Cytokine profiling showed a heterogeneous increase in interleukin (IL)-6, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-18, IL-2Ra, IL-10, and IL-1Ra that tended to normalize after treatment. Our study shows that children with MIS-C have elevated plasma levels of pro- and anti-inflammatory cytokines in the acute phase of the disease without other relevant immunologic disturbances. These findings suggest the presence of a mixed antagonist response syndrome (MARS) similar to that present in pediatric sepsis. Combining a meticulous differential diagnosis with cautiously coordinated immunomodulatory therapy and high-quality supportive care can help clinicians avoid causing iatrogenic harm in patients with MIS-C.

Keywords

cytokines - severe acute respiratory syndrome-coronavirus-2 - novel coronavirus 2019 - MIS-C - shock

• References

• 1 Rowley AH. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat Rev Immunol 2020; 20 (08) 453-454
• 2 Diorio C, Henrickson SE, Vella LA. et al. Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2. J Clin Invest 2020; 130 (11) 5967-5975
• 3 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383 (04) 334-346
• 4 Li Y, Zheng Q, Zou L. et al. Kawasaki disease shock syndrome: clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr Rheumatol Online J 2019; 17 (01) 1
• 5 Seishima M, Kato G, Shibuya Y, Matsukawa S. Cytokine profile during the clinical course of toxic shock syndrome. Clin Exp Dermatol 2009; 34 (08) e632-e635
• 6 World Health Organization. Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. Accessed May 16, 2020 at: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
• 7 Li H, Chen C, Hu F. et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia 2020; 34 (06) 1503-1511
• 8 Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am 2012; 59 (02) 329-344
• 9 Chaudhry H, Zhou J, Zhong Y. et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 2013; 27 (06) 669-684
• 10 Remy S, Kolev-Descamps K, Gossez M. et al. Occurrence of marked sepsis-induced immunosuppression in pediatric septic shock: a pilot study. Ann Intensive Care 2018; 8 (01) 36-36
• 11 Osuchowski MF, Craciun F, Weixelbaumer KM, Duffy ER, Remick DG. Sepsis chronically in MARS: systemic cytokine responses are always mixed regardless of the outcome, magnitude, or phase of sepsis. J Immunol 2012; 189 (09) 4648-4656
• 12 Cheung EW, Zachariah P, Gorelik M. et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City. JAMA 2020; 324 (03) 294-296
• 13 Richens N, Chikermane A, Duncan HP. et al. Critical care course of pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 and response to immunomodulation. J Pediatr Intensive Care 2022; 11 (02) 124-129
• 14 Ahmed M, Advani S, Moreira A. et al. Multisystem inflammatory syndrome in children: a systematic review. EClinicalMedicine 2020; 26 (00) 100527-100527
• 15 Riollano-Cruz M, Akkoyun E, Briceno-Brito E. et al. Multisystem inflammatory syndrome in children related to COVID-19: a New York City experience. J Med Virol 2020; x: x
• 16 Carcillo JA, Simon DW, Podd BS. How we manage hyperferritinemic sepsis-related multiple organ dysfunction syndrome/macrophage activation syndrome/secondary hemophagocytic lymphohistiocytosis histiocytosis. Pediatr Crit Care Med 2015; 16 (06) 598-600
• 17 Carcillo JA, Kernan KK, Horvat CM, Simon DW, Aneja RK. Why and how is hyperferritinemic sepsis different from sepsis without hyperferritinemia?. Pediatr Crit Care Med 2020; 21 (05) 509-512
• 18 Weiss SL, Peters MJ, Agus MSD. et al; Children's Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children Taskforce. Perspective of the surviving sepsis campaign on the management of pediatric sepsis in the era of coronavirus disease 2019. Pediatr Crit Care Med 2020; 21 (11) e1031-e1037
• 19 Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020; 323 (22) 2249-2251
• 20 Kim KD, Zhao J, Auh S. et al. Adaptive immune cells temper initial innate responses. Nat Med 2007; 13 (10) 1248-1252
• 21 Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol 2016; 16 (10) 626-638